Illumina Inc ILMN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ILMN is a good fit for your portfolio.
News
-
Walt Disney Nominates 12 to Board of Directors, Says CEO Iger's Compensation Doubled in 2023
-
Illumina to sell cancer-test maker Grail after latest antitrust ruling
-
Illumina Submits SEC Form For Grail Divestiture
-
As Illumina stock bounces off a 10-year low, analysts see no quick fix
-
Illumina's stock on track for lowest close in 10 years after cutting guidance
-
Illumina shares fall as company cuts forecasts
-
Illumina Gets European Commission Order to Divest Grail
-
Illumina responds to EC Grail divestiture order
Trading Information
- Previous Close Price
- €105.40
- Day Range
- €103.54–105.46
- 52-Week Range
- €86.09–198.58
- Bid/Ask
- €103.10 / €103.92
- Market Cap
- €16.49 Bil
- Volume/Avg
- 0 / 2
Key Statistics
- Price/Earnings (Normalized)
- 127.69
- Price/Sales
- 3.96
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 9,300
- Website
- https://www.illumina.com
Competitors
Valuation
|
Metric
|
ILMN
|
TMO
|
GH
|
|---|---|---|---|
Price/Earnings (Normalized) | 127.69 | 27.62 | — |
Price/Book Value | 3.10 | 5.01 | 46.80 |
Price/Sales | 3.96 | 5.44 | 5.07 |
Price/Cash Flow | 38.16 | 26.64 | — |
Price/Earnings
ILMN
TMO
GH
Financial Strength
|
Metric
|
ILMN
|
TMO
|
GH
|
|---|---|---|---|
Quick Ratio | 1.18 | 1.19 | 6.11 |
Current Ratio | 1.75 | 1.70 | 6.54 |
Interest Coverage | −15.22 | 4.83 | −198.43 |
Quick Ratio
ILMN
TMO
GH
Profitability
|
Metric
|
ILMN
|
TMO
|
GH
|
|---|---|---|---|
Return on Assets (Normalized) | 1.28% | 8.69% | −17.37% |
Return on Equity (Normalized) | 2.25% | 18.71% | −213.40% |
Return on Invested Capital (Normalized) | 1.78% | 10.97% | −22.39% |
Return on Assets
ILMN
TMO
GH
Diagnostics & Research Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
TMO
| Thermo Fisher Scientific Inc | Vzhcvwrtn | Mwh | $227.2 Bil | |
DHR
| Danaher Corp | Fgslgdlqy | Tgmvbx | $196.9 Bil | |
A
| Agilent Technologies Inc | Fkcqrcslyr | Tjbr | $45.2 Bil | |
IDXX
| IDEXX Laboratories Inc | Qpyckrrb | Vyvvk | $44.9 Bil | |
IQV
| IQVIA Holdings Inc | Rxzlxbx | Wllpvn | $42.8 Bil | |
MTD
| Mettler-Toledo International Inc | Hzrjrtxx | Hzgrp | $32.5 Bil | |
ICLR
| Icon PLC | Yjcqhgyk | Ghbsr | $26.0 Bil | |
WAT
| Waters Corp | Fzmlrxkxwn | Pprh | $21.1 Bil | |
LH
| Laboratory Corp of America Holdings | Stbrxwty | Jqqvh | $17.8 Bil | |
ILMN
| Illumina Inc | Kdlcqmy | Ndgwdf | $17.7 Bil |